---
title: "Vivalyx: Developer of Omnisol, an investigational perfusion solution for preserving donor organs"
url: https://emrr.uz/vivalyx?lang=uz
language: uz
updated: 2026-11-18T13:51:01Z
source: emrr (https://emrr.uz)
---

# Vivalyx

Developer of Omnisol, an investigational perfusion solution for preserving donor organs

[vivalyx.com](https://www.vivalyx.com/)

- **Soha**: Biotech, MedTech
- **Tashkil etilgan**: 2022
- **Joylashuv**: Germany

## Tasdiqlangan daromad: hali ulanmagan

Vivalyx sizningmi? Ushbu sahifani soʻrang va Stripe, App Store yoki Google Play’ni ulang: MRR va oʻsishingiz shu yerda toʻgʻridan-toʻgʻri manbadan koʻrinadi.

[Sizniki boʻlsa, soʻrang](https://panel.emrr.uz/reserve/vivalyx)

## Startap haqida

Vivalyx develops Omnisol, a blood-replacing perfusion solution designed to preserve and revitalise donor organs for transplantation. Omnisol is investigational and has entered first-in-human clinical use. The company is based in Aachen, Germany and is backed by Armenia-based Granatus Ventures.

## Jamoa

- **Andreas Schumacher**, Co-founder and CEO (Asoschi)
- **Benedict Doorschodt**, Co-founder and CTO (Asoschi)
- **René Tolba**, Co-founder and CMO (Asoschi)
- **Christian Bleilevens**, Co-founder and CSO (Asoschi)
- **Malte Brettel**, Co-founder (Asoschi)
- **Marius Rosenberg**, Co-founder (Asoschi)

## Auditoriya

Ijtimoiy tarmoqlardagi kuzatuvchilar

- [LinkedIn vivalyx](https://www.linkedin.com/company/vivalyx/)

Profil maʼlumotlari manbasi: Stanbase.

2026-yil 18-noyabr yangilangan

[Bu sahifa Markdown formatida](https://emrr.uz/vivalyx.md?lang=uz)

[Tasdiqlangan sahifa ochish](https://emrr.uz/?lang=uz): Stripe, App Store yoki Google Play’ni ikki daqiqada ulang va xuddi shunday sahifaga ega boʻling. emrr har bir raqamni oʻzi oʻqiydi, shuning uchun investorlar raqamlaringizga ishonishi mumkin. $1,000 MRR’gacha bepul.
